Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Guidelines for the management of myeloproliferative neoplasms.

The Korean journal of internal medicine - 1 Nov 2015

Choi Chul Won, Bang Soo-Mee, Jang Seongsoo, Jung Chul Won, Kim Hee-Jin, Kim Ho Young, Kim Soo-Jeong, Kim Yeo-Kyeoung, Park Jinny, Won Jong-Ho

Abstract excerpt

Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as 'Philadelphia-negative classical myeloproliferative neoplasms (MPNs).' The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Asian People

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Molecular Targeted Therapy

Share to Myeloproliferative Disorders

Share to Protein Kinase Inhibitors

Share to Republic of Korea

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26552452
DOI: 10.3904/kjim.2015.30.6.771
PMCID: PMC4642006

Genes

JAK2
JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Guidelines for the management of myeloproliferative neoplasms.PMID 26552452Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm VariantsSemantic proximity Read ↗

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]Semantic proximity Read ↗

Pathology consultation on myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemiaSemantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.